

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

T24

RRID:CVCL_0554

Type: Cell Line

Proper Citation

RRID:CVCL_0554

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0554

Proper Citation: RRID:CVCL_0554

Description: Cell line T24 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Bladder carcinoma

Defining Citation: [PMID:77569](#), [PMID:571047](#), [PMID:651066](#), [PMID:663932](#), [PMID:833871](#), [PMID:864752](#), [PMID:870558](#), [PMID:2607719](#), [PMID:3518877](#), [PMID:3708594](#), [PMID:4133950](#), [PMID:6220172](#), [PMID:6244232](#), [PMID:6823318](#), [PMID:6826254](#), [PMID:7017212](#), [PMID:7185004](#), [PMID:7787250](#), [PMID:8873383](#), [PMID:9247707](#), [PMID:9290701](#), [PMID:9850064](#), [PMID:11416159](#), [PMID:11921286](#), [PMID:12068308](#), [PMID:15846775](#), [PMID:16885334](#), [PMID:19105184](#), [PMID:19375735](#), [PMID:22460905](#), [PMID:23401075](#), [PMID:24018021](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:24376083](#), [PMID:24459064](#), [PMID:25997541](#), [PMID:26055179](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29732388](#), [PMID:30193179](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian; Swedish., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: T24

Synonyms: T-24, T 24

Cross References: BTO:BTO_0001345, CLO:CLO_0009235, CLO:CLO_0009245, CLO:CLO_0050843, CLO:CLO_0050844, EFO:EFO_0002864, MCCL:MCC:0000455, CLDB:cl4452, ABM:T8988, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-4, BCRC:60062, BCRJ:0231, BioGRID_ORCS_Cell_line:360, BioSample:SAMN03472744, BioSample:SAMN03473324, BioSample:SAMN10987918, cancercellines:CVCL_0554, CCLV:CCLV-RIE 0062, CCRID:1101HUM-PUMC000295, CCRID:3101HUMSCSP536, CCRID:3101HUMTCHu55, CCRID:4201HUM-CCTCC00078, CCRID:5301HUM-KCB92027YJ, CCTCC:GDC0078, Cell_Model_Passport:SIDM01184, ChEMBL-Cells:ChEMBL3307700, ChEMBL-Targets:ChEMBL614774, CLS:300352, Cosmic:716174, Cosmic:724812, Cosmic:755400, Cosmic:845561, Cosmic:846275, Cosmic:925832, Cosmic:928817, Cosmic:943742, Cosmic:1001664, Cosmic:1016880, Cosmic:1046673, Cosmic:1285130, Cosmic:1285985, Cosmic:1302355, Cosmic:1927302, Cosmic:1938698, Cosmic:2037960, Cosmic:2050465, Cosmic:2057459, Cosmic:2444230, Cosmic:2686118, Cosmic:2700999, Cosmic-CLP:724812, DepMap:ACH-000018, DSMZ:ACC-376, DSMZCellDive:ACC-376, EGA:EGAS00001000978, GDSC:724812, GEO:GSM136233, GEO:GSM492493, GEO:GSM887683, GEO:GSM888775, GEO:GSM1374940, GEO:GSM1574571, GEO:GSM1670520, IARC_TP53:3722, IARC_TP53:21131, IARC_TP53:30178, JCRB:JCRB0711, KCB:KCB 92027YJ, KCLB:30004, LiGeA:CCLE_255, LINCS_HMS:50048, LINCS_LDP:LCL-1709, Lonza:862, Pharmacodb:T24_1554_2019, PRIDE:PXD003105, PRIDE:PXD030304, Progenetix:CVCL_0554, PubChem_Cell_line:CVCL_0554, RCB:RCB0431, RCB:RCB2536, TKG:TKG 0443, TOKU-E:3252, Ubigen:YC-C044, Wikidata:Q54971454

ID: CVCL_0554

Record Creation Time: 20220427T221618+0000

Record Last Update: 20260905T182529+0000

Ratings and Alerts

No rating or validation information has been found for T24.

No alerts have been found for T24.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 106 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Schmitz J, et al. (2026) Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. *Molecular oncology*, 20(3), 779.

Chen Z, et al. (2026) Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma. *Cell reports. Medicine*, 7(4), 102712.

Wang JS, et al. (2026) HSPB6: A Potential Prognostic Biomarker, Inhibiting the Epithelial-Mesenchymal Transition (EMT) Process Through the PI3K/Akt Signaling Pathway Based on the Machine Learning and Experimental Validation. *Human mutation*, 2026, 4843618.

O'Callaghan LA, et al. (2026) The Antipsychotic Aripiprazole Induces Cytotoxicity in Bladder Cancer Cells While Preserving Urothelial and Bladder Function. *Pharmacology research & perspectives*, 14(3), e70260.

Chen Z, et al. (2026) An AI-Driven Multi-Omics Framework Identifies CASP8 as a Clinically Actionable Pyroptosis Biomarker in Bladder Cancer. *BioFactors (Oxford, England)*, 52(4), e70130.

Ying X, et al. (2026) m5C-Modified tRF3b-CysGCA-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(26), e22294.

Jin Z, et al. (2026) HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothed. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(1), e71388.

Qin X, et al. (2026) A 'two-in-one' tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues. *Journal of nanobiotechnology*, 24(1).

Xu G, et al. (2026) Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer. *Cell reports*, 45(2), 116941.

Cui S, et al. (2026) A Novel FGFR3-Targeting Antibody-Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS-STING Pathway in Bladder Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(4), e09933.

Wu J, et al. (2026) O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(37), e19955.

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Zhao B, et al. (2026) XPC Deficiency Activate Cisplatin-Mediated Autophagy in Bladder Cancer by Limiting Novel PHRF1-Mediated Ubiquitination of the p53 Protein. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(5), e17563.

Lin WW, et al. (2026) Design and Synthesis of N-Heteroacridone Derivatives and Their Ferroptosis-Inducing Activity Against Human Melanoma. *ChemMedChem*, 21(11), e202501070.

Guo D, et al. (2026) The Physicochemical Synergy Effect of Nanosecond Pulsed Electric Fields (nsPEF) and cisplatin on reversing chemoresistance of bladder cancer. PloS one, 21(4), e0346699.

Li Z, et al. (2026) Engineered pistol ribozymes selectively target KRAS G12V with enhanced efficacy by capping modification. Cell chemical biology, 33(5), 671.

Barlak BSR, et al. (2026) Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into the Acquisition of Cancer Stem-like States and Phenotypic Plasticity. Cancer genomics & proteomics, 23(2), 300.

Yamanaka R, et al. (2026) Angiotensin II type 1 receptor signaling promotes bladder cancer progression and its inhibition by Losartan. Hypertension research : official journal of the Japanese Society of Hypertension, 49(4), 1480.

Pece A, et al. (2026) Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. Molecular oncology, 20(3), 823.

Fu H, et al. (2026) A smart gene circuit for precise regulation of tumor cell behavior. Synthetic and systems biotechnology, 11, 237.